HTA

Germany drug pricing policies are now the subject of a US Section 301 investigation. AbbVie's chief counsel, Perry Siatis, has filed written evidence and testified that government price setting, mandatory rebates and reimbursement restrictions undercut the incentives that fund new medicines. He also cites a German-French working group on keeping innovative medicines available. #SyenzaNews #MarketAccess #DrugPricing #HEOR

Mounjaro passed €1 million in pharmacy sales in a single day in Portugal, on more than 3,000 packs, and the Ordem dos Médicos has asked Infarmed for prescription data. Here is what the numbers show on access, reimbursement and supply. #SyenzaNews #GLP1 #MarketAccess

Syenza's webinar on AI governance in HTA drew 71% of participants who had not yet used AI in their work. The session covered the paper's governance checklist, the in-house Navigator tool, and a live rapid HTA of rituximab in lupus. #SyenzaNews #HTA #AIinHealth #MarketAccess

South Africa has set a second single exit price adjustment for 2026, lifting listed medicine prices by 2.88% from 1 October. #SyenzaNews #MarketAccess #Pharma

HTAsiaLink 2026 brought HTA agencies, researchers and patient representatives together in Taipei to weigh real-world evidence, AI and patient involvement against the realities of different Asia-Pacific health systems. #HTA #HealthEconomics #MarketAccess

Nigeria's NHIA has inaugurated a national health technology assessment steering committee to anchor healthcare spending in evidence. #SyenzaNews #HTA #HealthEconomics #Nigeria

The European Commission has published three templates that formalise written input from patients, carers and clinicians in EU Joint Clinical Assessments, locking it onto the scope proposal and the draft report. #HTA #JCA #MarketAccess

NICE has reversed its earlier rejection and now recommends Enhertu (trastuzumab deruxtecan) as a routine NHS option for HER2-low metastatic breast cancer after chemotherapy. The change follows an updated commercial deal and new EQ-5D-5L utility values validated in the DESTINY-Breast04 trial. #SyenzaNews #HTA #MarketAccess #BreastCancer

Spain's Real Decreto 415/2026 makes patient involvement in HTA a legal requirement. Speakers from POP, Cancer Patients Europe, BMS and NICE explain how plain-language summaries keep that involvement meaningful.

The FDA's landmark hearing on psychedelic medicines drew 80 speakers and 1,800 registrants, and the market access message was clear: approval is not access, and reimbursement is the binding constraint. #SyenzaNews #MarketAccess #Psychedelics #HealthPolicy

NICE has opened consultation on draft guidance that does not recommend lenacapavir for HIV PrEP, finding the six-monthly injection is not value for money for the NHS in England. #SyenzaNews #HTA #HIV #PrEP #MarketAccess

Alec Morton of NUS explains how AI is changing health technology assessment, what stays human, and why cheaper analysis could mean more health economics.